This is a paid press release. Contact the press release distributor directly with any inquiries.
New GLP-1 Clinical Study Finds Calocurb® Reduces Body Weight and Body Fat Without Loss of Muscle Mass
Business Wire
Fri, July 24, 2026 at 2:05 AM GMT+5:30
5 min read
The natural GLP-1 activator is clinically shown to support fat loss, including visceral fat reduction, while preserving lean muscle
AUCKLAND, New Zealand, July 23, 2026–(BUSINESS WIRE)–Calocurb, the New Zealand-based company bringing the world the first 100% natural GLP-1 activator, announces today the publication of a new clinical study in US medical journal, Obesity Pillars, demonstrating Calocurb’s effectiveness in weight loss and muscle preservation. In the brand’s fourth human clinical study users saw an average weight loss of 8.3 lbs (3.77 kg) after six months of consistent use paired with ‘real world’ healthy diet and exercise advice. There was no loss in muscle mass.
Calocurb is derived from a patented bitter hops extract called Amarasate®, first identified as part of an extensive research programme funded by the New Zealand government. Unlike prescription GLP-1 medications, Calocurb works by significantly stimulating 3 of the body’s own natural satiety hormones (GLP-1, CCK, PYY) by activating bitter taste receptors in the L-cells of the gastrointestinal tract, to reduce hunger, cravings and calorie intake
The randomized, double-blind clinical trial undertaken by a research institute of the New Zealand government, evaluated Calocurb over 24 weeks with a three-month follow-up on all participants. Those who took Calocurb experienced significantly greater reductions in body weight, body fat, and visceral fat, and also maintained muscle mass, compared to the placebo group. This is a major feat in the weight management space, as synthetic GLP-1 medications have been shown to decrease muscle mass, potentially leading to long-term issues with mobility and bone health. Key results from Calocurb’s fourth human clinical study include the following:
Calocurb is clinically shown to improve body composition by reducing body fat without losing muscle mass
Average weight loss of 8.3 lbs (3.77 kg) after six months, compared to 0.88 lbs (0.4 kg) with the placebo group
Over 6.5x greater reduction in body fat vs placebo
Average body fat loss of 9.9 lbs (4.49 kg) vs 1.5 lbs (0.68 kg) after six months of consistent use of Calocurb vs placebo
3.5x greater reduction in visceral fat vs placebo
Average visceral fat loss of 5 in2 (32.5 cm2) vs 1.4 in2 (9.1 cm2) lost after six months of consistent use of Calocurb vs placebo
For over a decade, Calocurb has undertaken ground-breaking clinical research into Amarasate® to continue bringing natural weight management solutions to those interested in GLP-1 and weight loss options
